Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Return on Equity (2016 - 2025)

Historic Return on Equity for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to 0.31%.

  • Dexcom's Return on Equity rose 200.0% to 0.31% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.31%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.34% for FY2025, which is 700.0% up from last year.
  • Per Dexcom's latest filing, its Return on Equity stood at 0.31% for Q4 2025, which was up 200.0% from 0.27% recorded in Q3 2025.
  • In the past 5 years, Dexcom's Return on Equity ranged from a high of 0.37% in Q1 2021 and a low of 0.1% during Q2 2022
  • Its 5-year average for Return on Equity is 0.23%, with a median of 0.25% in 2025.
  • Per our database at Business Quant, Dexcom's Return on Equity surged by 2000bps in 2021 and then crashed by -2600bps in 2022.
  • Quarter analysis of 5 years shows Dexcom's Return on Equity stood at 0.11% in 2021, then surged by 57bps to 0.17% in 2022, then surged by 45bps to 0.25% in 2023, then increased by 13bps to 0.28% in 2024, then rose by 8bps to 0.31% in 2025.
  • Its Return on Equity stands at 0.31% for Q4 2025, versus 0.27% for Q3 2025 and 0.24% for Q2 2025.